Sumitomo Chemical Group Wins World’s First iPS Cell Therapy Approval for Parkinson’s in Japan

The latest update is out from Sumitomo Chemical Co ( (JP:4005) ).

Sumitomo Chemical said its subsidiary Sumitomo Pharma has secured conditional, time‑limited manufacturing and marketing authorization in Japan for AMCHEPRY, an allogeneic iPS cell‑derived dopaminergic neural progenitor cell therapy for Parkinson’s disease patients who respond inadequately to existing drugs. The approval, based on Kyoto University Hospital clinical data and supported by Japanese government programs, is the world’s first for an iPS cell‑derived regenerative medicine product and is expected to underpin blockbuster‑level sales in the 2030s while strengthening the group’s leadership in regenerative and cellular therapies.

Sumitomo Pharma will handle marketing after national reimbursement listing, S‑RACMO will manage commercial production, and the company plans post‑marketing studies and surveillance to convert the conditional approval into full approval. Sumitomo Chemical, Sumitomo Pharma, RACTHERA and S‑RACMO aim to leverage this milestone to expand their regenerative medicine franchise, offering a novel treatment option for Parkinson’s disease and enhancing their competitive positioning in advanced healthcare solutions.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen513.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

More about Sumitomo Chemical Co

Sumitomo Chemical Co., Ltd. is a diversified Japanese chemical group with a growing focus on healthcare, where it has positioned regenerative medicine and cell therapy as core medium- to long-term growth drivers. Through majority stakes in Sumitomo Pharma, RACTHERA and S-RACMO, the company is building an integrated value chain from stem cell research to commercial manufacturing of advanced regenerative and cellular therapies.

Average Trading Volume: 13,584,785

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen836.9B

For an in-depth examination of 4005 stock, go to TipRanks’ Overview page.